Table 2.

Fold-changes in protein expression following ganetespib treatment in RT112 bladder cancer cells using reverse-phase protein array analysis

Cellular targetProteinFold change
Receptor tyrosine kinasesMET (pY1235)−2.7
HER2−2.2
HER2 (pY1248)−2.2
EGFR (pY1068)−1.9
HER3−1.6
EGFR−1.5
AKT SignalingAKT (pS473)−2.5
AKT−2.4
GSK3-A/B (pS2/S9)−1.8
PDK1 (pS241)−1.7
GSK3-A/B−1.5
PDK1−1.4
MAPK PathwayC-RAF−1.8
MAPK (pT202/Y204)−1.5
MEK1 (pS217/S221)−1.4
Src (pY527)−1.4
P90RSK (pT359/S363)−1.4
Transcription factorsc-Myc−2.5
NF-κB p65 (pS536)−2.3
S6 (pS235/S236)−13.2
S6 (pS240/S244)−8.9
P70S6K (pT389)−4.7
mTOR Pathway4E-BP1 (pS65)−2.5
mTOR (pS2448)−2.2
Tuberin−2.2
TSC1−1.3
PRAS40 (pT246)−1.2
Cell cycle regulationRb (pS807/811)−4.6
Chk1−3.2
Cyclin B1−1.9
CDK1−1.4
p21+1.4
p27+1.5
Stress responseHSP70/72+3.0
HSP90 alpha+1.6
ApoptosisCaspase-7 (cleaved D198)+2.5
BIM+1.4